Want to see BNTC full AI Analyst Report?
BNTC Stock Chart & Stats
$14.08
<$0.01(0.09%)
At close: 4:00 PM EST
$14.08
<$0.01(0.09%)
Day’s Range― - ―
52-Week Range$9.85 - $16.76
Previous CloseN/A
Volume10.71K
Average Volume (3M)131.05K
Market Cap
$453.48M
Enterprise Value$125.83M
Total Cash (Recent Filing)$184.76M
Total Debt (Recent Filing)$876.00K
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Sep 30, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding34,354,336
10 Day Avg. Volume222,155
30 Day Avg. Volume131,046
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-264.91
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$25.00Price Target Upside77.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.99
Revenue Forecast (FY)$27.32M
Bulls Say, Bears Say
Bulls Say
Proprietary DdRNAi PlatformBenitec’s ddRNAi platform is a durable scientific asset that can support multiple therapeutic programs and licensing opportunities. A validated platform creates scalable R&D optionality, attracts partnerships, and concentrates development risk on platform-level success rather than single-product dependency.
Low Financial LeverageA very low debt burden and sizable equity/assets provide financial flexibility to fund continued R&D without immediate refinancing pressure. This structural cushion reduces near-term solvency risk and preserves options for strategic transactions or staged financing over months.
Improving Cash Burn And Initial RevenueOperating and free cash flow improved versus the prior year and the TTM shows at least some revenue, signaling early operational progress. While still negative, the trend toward lower cash outflows and emerging revenue is a durable indicator of incremental operational discipline and runway extension.
Bears Say
Large Operating LossesPersistent, sizable operating losses relative to negligible revenue indicate the business remains pre-commercial and must rely on financing to sustain R&D. Structural unprofitability erodes equity over time and raises execution risk if clinical or regulatory progress slows.
Negative Free Cash FlowConsistent negative operating and free cash flow creates a structural need for external funding, which can lead to dilution, restrictive financing terms, or constrained R&D pacing. Over a multi-month horizon, this funding dependence is a core risk to program continuity and strategic flexibility.
Board Turnover During Governance ReviewGovernance changes and a director resignation during an active board composition review can signal strategic reassessment or internal friction. Leadership turnover at the board level may introduce short-term strategy shifts, distract management, and bring incremental compensation costs (option grants), affecting execution consistency.
Benitec Biopharma News
BNTC FAQ
What was Benitec Biopharma’s price range in the past 12 months?
Benitec Biopharma lowest stock price was $9.85 and its highest was $16.76 in the past 12 months.
What is Benitec Biopharma’s market cap?
Benitec Biopharma’s market cap is $453.48M.
When is Benitec Biopharma’s upcoming earnings report date?
Benitec Biopharma’s upcoming earnings report date is Sep 30, 2026 which is in 83 days.
How were Benitec Biopharma’s earnings last quarter?
Benitec Biopharma released its earnings results on May 14, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.028.
Is Benitec Biopharma overvalued?
According to Wall Street analysts Benitec Biopharma’s price is currently Undervalued.
Does Benitec Biopharma pay dividends?
Benitec Biopharma pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma dividends here
What is Benitec Biopharma’s EPS estimate?
Benitec Biopharma’s EPS estimate is -0.28.
How many shares outstanding does Benitec Biopharma have?
Benitec Biopharma has 34,354,336 shares outstanding.
What happened to Benitec Biopharma’s price movement after its last earnings report?
Benitec Biopharma reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went up 1.717%.
Which hedge fund is a major shareholder of Benitec Biopharma?
Currently, no hedge funds are holding shares in BNTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Benitec Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (77.56% Upside)
$25.00 (77.56% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 76.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.22%
12-Months-Change
Fundamentals
Return on Equity
-34.82%
Trailing 12-Months
Asset Growth
77.74%
Trailing 12-Months
Company Description
Benitec Biopharma
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
BNTC Stock 12 Month Forecast
Average Price Target
$25.00
▲(77.56% Upside)
Technical Analysis
Tvardi Therapeutics
―
Assembly Biosciences
―
Rocket Pharmaceuticals
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
5.61% Insiders
8.75% Mutual Funds
60.75% Other Institutional Investors
16.21% Public Companies and
Individual Investors